PP
ARMP icon

Paloma Partners’s Armata Pharmaceuticals ARMP Stock Holding History

Paloma Partners’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,350
Closed -$10K – 1673
2018
Q4 		$10K Buy
+3,350
New +$16.3K ﹤0.01% 1199

Other funds holding ARMP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SXL
Summit X LLC Chesterfield, Missouri $536M AUM 15.36% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Paloma Partners's ARMP Position: Q1 2019 in Review

Paloma Partners sold out of Armata Pharmaceuticals (ARMP) in Q1 2019, closing a stake of 3,350 shares — an estimated $10K sold.

Paloma Partners first reported a position in ARMP in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 25 funds tracked by Wall St. Rank hold ARMP as of Q1 2019.

  • Paloma Partners reported no remaining Armata Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Paloma Partners sold 3,350 Armata Pharmaceuticals shares in Q1 2019, an estimated $10K.
  • Paloma Partners first reported a position in Armata Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Paloma Partners's Armata Pharmaceuticals position peaked at $10K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.